Changmao Biochemical Engineering Co Ltd

Changmao Biochemical Engineering Co Ltd exhibits a capital structure with a debt-to-equity ratio of 1.04, indicating a moderate reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.5, suggesting that it may struggle to meet short-term obligations without external financing. Free cash flow is negative at -23.07 million CNY, and operating cash flow is only 19.52 million CNY, indicating limited internal liquidity generation. Profitability metrics are severely underperforming relative to industry norms. The company reported a net loss of 66.76 million CNY and an operating loss of 48.37 million CNY, with a return on equity of -12.92% and a return on assets of -5.66%. These figures suggest that the company is not generating returns that meet the cost of capital, and its performance is likely below the median for the Commodity Chemicals industry. The company's revenue is concentrated in a few geographic regions, with disclosed operations in Europe, Asia Pacific, and America. However, the financial snapshot does not provide a breakdown of revenue by segment or region, making it difficult to assess the degree of concentration risk. The lack of detailed segment reporting limits the ability to evaluate exposure to specific markets or products. Growth prospects appear muted. The company's recent revenue of 556.93 million CNY is below the analyst estimate of 320.69 million CNY, suggesting a potential discrepancy in expectations or reporting. The outlook for the current and next fiscal years is not provided, but the negative net income and operating cash flow indicate a challenging operating environment. The company may need to improve cost efficiency or expand into higher-margin markets to drive growth. Risk factors include liquidity constraints and the potential for dilution, although the latter is currently assessed as low. The company's net cash position is negative after subtracting total debt, and the free cash flow is insufficient to cover capital expenditures. These factors increase the risk of financial distress, particularly if operating performance does not improve. The absence of a detailed dilution risk assessment in the input data suggests that the company has not disclosed significant dilution pressures in recent filings. Recent events and disclosures are limited in the provided data. The company's latest actual EPS was 0.10 CNY, and the actual revenue was 320.69 million CNY, both of which are below the reported revenue of 556.93 million CNY. This discrepancy may indicate a need for further investigation into the accuracy of financial reporting or the timing of revenue recognition. No recent filings or transcripts are provided to assess management commentary or strategic direction.